- Home
- ARHS vs MLYS Comparison
ARHS vs MLYS Comparison
Compare ARHS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- MLYS
- Stock Information
- Founded
- ARHS 1986
- MLYS 2019
- Country
- ARHS United States
- MLYS United States
- Employees
- ARHS N/A
- MLYS 51
- Industry
- ARHS Other Specialty Stores
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ARHS Consumer Discretionary
- MLYS Health Care
- Exchange
- ARHS Nasdaq
- MLYS Nasdaq
- Market Cap
- ARHS 1.1B
- MLYS 1.0B
- IPO Year
- ARHS 2021
- MLYS 2023
- Fundamental
- Price
- ARHS $8.98
- MLYS $15.58
- Analyst Decision
- ARHS Buy
- MLYS Strong Buy
- Analyst Count
- ARHS 13
- MLYS 3
- Target Price
- ARHS $11.08
- MLYS $33.00
- AVG Volume (30 Days)
- ARHS 2.0M
- MLYS 866.7K
- Earning Date
- ARHS 05-08-2025
- MLYS 05-12-2025
- Dividend Yield
- ARHS N/A
- MLYS N/A
- EPS Growth
- ARHS N/A
- MLYS N/A
- EPS
- ARHS 0.41
- MLYS N/A
- Revenue
- ARHS $1,287,317,000.00
- MLYS N/A
- Revenue This Year
- ARHS $7.07
- MLYS N/A
- Revenue Next Year
- ARHS $7.71
- MLYS N/A
- P/E Ratio
- ARHS $21.91
- MLYS N/A
- Revenue Growth
- ARHS 0.71
- MLYS N/A
- 52 Week Low
- ARHS $6.61
- MLYS $8.24
- 52 Week High
- ARHS $19.81
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- ARHS 58.50
- MLYS 54.41
- Support Level
- ARHS $7.94
- MLYS $15.45
- Resistance Level
- ARHS $8.99
- MLYS $16.11
- Average True Range (ATR)
- ARHS 0.41
- MLYS 0.96
- MACD
- ARHS 0.07
- MLYS -0.05
- Stochastic Oscillator
- ARHS 88.89
- MLYS 51.56
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.